Netherton syndrome: Successful use of topical tacrolimus ... - Colleges

Saif and Al-Khenaizan
tacrolimus after topical application in a patient with lamellar
ichthyosis. Arch Dermatol 2002; 138:
1259–1260.
5 Allen A, Siegfried E, Silverman R, et al. Significant
absorption of topical tacrolimus in 3 patients with
Netherton syndrome. Arch Dermatol 2001; 137:
747–750.
6 Bens G, Boralevi F, Buzenet C, et al. Topical treatment of
Netherton’s Syndrome with tacrolimus ointment without
significant systemic absorption. Br J Dermatol 2003;
149:
224–226.
7 Sybert VP. Disorders of the epidermis. In: Sybert VP, ed.
Genetic Skin Disorders.
New York, Oxford: Oxford
University Press, 1997: 5–128.
8 Greene SL, Muller SA. Netherton’s syndrome. Report of a
case and review of the literature. J Am Acad Dermatol 1985;
13:
329–337.
9 Caputo R, Vanotti P, Bertani E. Netherton’s syndrome in
two adult brothers. Arch Dermatol 1984; 120:
220–222.
10 Brodin MB, Porter PS. Netherton’s syndrome. Cutis 1980;
26:
185–188, 191.
11 Kassis V, Nielsen JM, Klem-Thomsen H, et al. Familial
Netherton’s disease. Cutis 1986; 38:
175–178.
12 Stankler L, Cochrane T. Netherton’s disease in two sisters.
Br J Dermatol 1967; 79:
187–196.
13 Plantin P, Delaire P, Guillet MH, et al. Netherton’s
syndrome. Current aspects. Apropos of 9 cases. Ann
Dermatol Venereol 1991; 118:
525–530.
14 Wehr RF, Hickman J, Krochmal L. Effective treatment of
Netherton’s syndrome with 12% lactate lotion. J Am Acad
Dermatol 1988; 19:
140–142.
15 Hausser I, Anton-Lamprecht I. Severe congenital generalized
exfoliative erythroderma in newborns and infants: a possible
sign of Netherton syndrome. Pediatr Dermatol 1996; 13:
183–199.
16 Judge MR, Morgan G, Harper JI. A clinical and
immunological study of Netherton’s syndrome. Br J
Dermatol 1994; 131:
615–621.
17 Curth HO. Netherton’s syndrome and ichthyosis linearis
circumflexa. Arch Dermatol 1970; 101:
485.
18 Jones SK, Thomason LM, Surbrugg SK, et al. Neonatal
hypernatraemia in two siblings with Netherton’s syndrome.
Br J Dermatol 1986; 114:
741–743.
19 Salamon T, Lazovic O, Stenek S. The Netherton Syndrome.
Hautarzt 1972; 23:
66–71.
20 Stryk S, Siegfried EC, Knutsen AP. Selective antibody
deficiency to bacterial polysaccharide antigens in patients
with Netherton syndrome. Pediatr Dermatol 1999; 16:
19–
22.
21 Ansai S, Mitsuhashi Y, Sasaki K. Netherton’s syndrome in
siblings. Br J Dermatol 1999; 141:
1097–1100.
22 Chavanas S, Garner C, Bodemer C, et al. Localization of the
Netherton syndrome gene to chromosome 5q32, by linkage
analysis and homozygosity mapping. Am J Hum Genet
2000; 66:
914–921.
23 Chavanas S, Bodemer C, Rochat A, et al. Mutations in
SPINK5, encoding a serine protease inhibitor, cause
Netherton syndrome. Nat Genet 2000; 25: 141–142.
Calcineurin inhibitors in Netherton syndrome
Case report
24 Bitoun E, Bodemer C, Amiel J, et al. Prenatal diagnosis of a
lethal form of Netherton syndrome by SPINK5 mutation
analysis. Prenat Diagn 2002; 22: 121–126.
25 Bitoun E, Chavanas S, Irvine AD, et al. Netherton syndrome:
Disease expression and spectrum of SPINK5 mutations in 21
families. J Invest Dermatol 2002; 118: 352–361.
26 Magert HJ, Standker L, Kreutzmann P, et al. LEKTI, A novel
15-domain type of human serine proteinase inhibitor. J Biol
Chem 1999; 274: 21499–21502.
27 Sprecher E, Chavanas S, DiGiovanna JJ, et al. The spectrum
of pathogenic mutations in SPINK5 in 19 families with
Netherton syndrome: Implications for mutation detection
and first case of prenatal diagnosis. J Invest Dermatol 2001;
117: 179–187.
28 Raghunath M, Tontsidou L, Oji V, et al. SPINK5 and
Netherton Syndrome: novel mutations, demonstration of
missing LEKTI, and differential expression of
transglutaminases. J Invest Dermatol 2004; 123: 474–483.
29 Suga Y, Tsuboi R, Hashimoto Y, et al. A case of Ichthyosis
linearis circumflexa successfully treated with topical
tacrolimus. J Am Acad Dermatol 2000; 42: 520–522.
30 Borzyskowski M, Grant DB, Wells RS. Cushing’s syndrome
induced by topical steroids used for the treatment of nonbullous
ichthyosiform erythroderma. Clin Exp Dermatol
1976; 1: 337–342.
31 Traupe H, Happle R. Etretinate therapy in children with
severe keratinization defects. Eur J Pediatr 1985; 143: 66–
69.
32 Hausser I, Anton-Lamprecht I, Hartschuh W, et al.
Netherton’s syndrome: ultrastructure of the active lesion
under retinoid therapy. Arch Dermatol Res 1989; 281: 165–
172.
33 Godic A, Dragos V. Successful treatment of Netherton’s
syndrome with topical calcipotriol. Eur J Dermatol 2004;
14: 115–117.
34 Nagata T. Netherton’s syndrome which responded
to photochemotherapy. Dermatologica 1980; 161:
51–56.
35 Braun RP, Ramelet AA. Failure of cyclosporine in
Netherton’s Syndrome. Dermatology 1997; 195: 75.
36 Buxman M, Hickman J, Ragsdale W, et al. Therapeutic
activity of lactate 12% lotion in the treatment of ichthyosis.
Active versus vehicle and active versus a petrolatum cream.
J Am Acad Dermatol 1986; 15: 1253–1258.
37 Smith DL, Smith JG, Wong SW, et al. Netherton’s
syndrome: a syndrome of elevated IgE and characteristic
skin and hair findings. J Allergy Clin Immunol 1995; 95:
116–123.
38 Marsland AM, Griffiths CE. The macrolide
immunosuppressants in dermatology: mechanisms of
action. Eur J Dermatol 2002; 12: 618–622.
39 Gupta AK, Adamiak A, Chow M. Tacrolimus: a review of its
use for the management of dermatoses. J Eur Acad Dermatol
Venereol 2002; 16: 100–114.
40 Grassberger M, Steinhoff M, Schneider D, et al.
Pimecrolimus an anti-inflammatory drug targeting the skin.
Exp Dermatol 2004; 13: 721–730.
© 2006 The International Society of Dermatology International Journal of Dermatology 2007, 46,
290–294
293